Conferences - Results from #460

Viewing 461-480 of 11775 articles

ASCO 2024: Investigation of T Cell Phenotypes Associated with Response or Resistance to Immune Checkpoint Inhibitors (ICI) Through Single-Cell Analysis of Renal Cell Carcinoma (RCC)

ASCO 2024: Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?

ASCO 2024: Preliminary Safety, Pharmacokinetics and Clinical Activity of DFF332, an Oral HIF2α Inhibitor, as Monotherapy in a Phase 1 Dose Escalation Study in Patients with Advanced Clear Cell Renal Cell Carcinoma.

ASCO 2024: A Multi-Institution Analysis of Outcomes With First-Line Systemic Therapy for 102 Patients With Metastatic Chromophobe Renal Cell Carcinoma

ASCO 2024: Camrelizumab plus Apatinib for Previously Treated Advanced Adrenocortical Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial.

ASCO 2024: Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer

ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)

ASCO 2024: Optimal Treatment Intensity for Frontline Therapy for Advanced Urothelial Cancer: Which Regimen for Which Patient?

ASCO 2024: Molecular Imaging for Prostate Cancer: When and Which Agents.

ASCO 2024: Responsible and Equitable Biomarker Stewardship: How Do We Ensure Access to All Patients

ASCO 2024: Practical Approach to Genetic Testing and Treatment Selection in Prostate Cancer.

ASCO 2024: Bladder-Sparing Treatment Strategies for Localized Urothelial Cancer

Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

AUA 2024: Key Takeaways for Sexual Dysfunction

CG Oncology to Present Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembro in BCG-Unresponsive High-Risk NMIBC

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

AUA 2024: Long-term Dementia Risk with Use of Anticholinergic versus Beta-3-Agonist Pharmacotherapy for Overactive Bladder

AUA 2024: EvoPAR-Prostate01: Phase III, Double-Blind, Placebo-Controlled, 2-Cohort, Randomized Study of Saruparib (AZD5305) in Combination with New Hormonal Agents in Patients with mCSPC +/- HRR Mutations

AUA 2024: State-of-the-Art Lecture: Lasers in Endourology

AUA 2024: Back to Medical School: Immunology in NMIBC and Neoadjuvant MIBC for the Urologist

19
20
21
22
23
24
25
26
27
28